Evidence map›Paper›PMID 26218419›Full record

ReviewCurrent opinion in lipidology2015

What does procollagen C-endopeptidase enhancer protein 2 have to do with HDL-cholesteryl ester uptake? Or how I learned to stop worrying and love reverse cholesterol transport?

Mary G Sorci-Thomas, Ricquita D Pollard, Michael J Thomas

Open access · hybridAbstract readReview
In one paragraph

Review in Current opinion in lipidology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Mary G Sorci-ThomasaDepartment of Medicine and Endocrinology bDepartment of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin cformerly of Wake Forest School of Medicine, Department of Molecular Medicine, Winston-Salem, North Carolina, USA.
Ricquita D Pollard
Michael J Thomas
Medical College of Wisconsin · USWake Forest University · US

Funding

T Regulatory Lymphocytes, HDL Function, and AtherosclerosisR01HL112276 · NHLBI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI HEDRICK, CATHERINE C, SORCI-THOMAS, MARY G · 2013 to 2016
$2.8M
Biophysics of HDL DysfunctionR01HL112270 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI PRITCHARD, KIRKWOOD ARTHUR, SORCI-THOMAS, MARY G · 2012 to 2015
$2.5M
Biogenesis of HDL Through Cholesterol Efflux and ApoA-I Structural ReorganizationR01HL127649 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI SORCI-THOMAS, MARY G · 2015 to 2018
$2.2M
NHLBI NIH HHS HL112270NHLBI NIH HHS HL112270A1-S1NHLBI NIH HHS HL-112276NHLBI NIH HHS HL127649
6 · The paper itself

Abstract

purpose of reviewThe purpose of this study is to provide an update on the role HDL apolipoprotein A-I plays in reducing the risk of cardiovascular disease (CVD) and how it relates to reverse cholesterol transport (RCT). RECENT

findingsDespite numerous studies showing that plasma HDL cholesterol concentrations are correlated with a reduced risk of CVD, pharmacologic elevation of HDL has not shown any beneficial effects to date. In contrast, studies correlating the measure of an individual's plasma cholesterol efflux capacity show greater promise as a tool for assessing CVD risk. Although ATP-binding cassette transporter 1-mediated lipidation of apoA-I is considered the principal source of plasma HDL, it represents only one side of the RCT pathway. Equally important is the second half of the RCT pathway in which the liver scavenger receptor class B1 selectively removes HDL cholesteryl esters for excretion. The combined action of the two enzyme systems is reflected in the overall steady-state concentration of plasma HDL cholesterol. For example, reduced ATP-binding cassette transporter 1-mediated production of nascent HDL lowers plasma HDL concentration, just as an increase in cholesteryl ester uptake by scavenger receptor class B1 reduces HDL levels. Thus, the complexity of intravascular HDL metabolism suggests that steady-state plasma HDL concentrations do not provide adequate information regarding an individual's HDL quality or function. Herein, we describe a new player, procollagen C-endopeptidase enhancer 2, which shows atheroprotective function and influences both sides of RCT by enhancing production and catabolism of HDL cholesteryl esters. SUMMARY: The discovery of a new molecule, procollagen C-endopeptidase enhancer 2, implicated in the regulation of HDL cholesteryl ester concentrations suggests that the extracellular matrix and the proteins that regulate its function represent a new and as yet unexplored realm of HDL cholesterol metabolism.

Indexed as

AnimalsAtherosclerosisBiological TransportCholesterol EstersExtracellular Matrix ProteinsGlycoproteinsHumansLipoproteins, HDLCholesterol EstersExtracellular Matrix ProteinsGlycoproteinsHDL cholesteryl esterLipoproteins, HDLPCOLCE2 protein, human

Identifiers

PMID26218419
PMCPMC4564020
OpenAlexW1014408074

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.